Morning | 9:00 am-12:00 pm

SC1: Introduction to GPCR-Based Drug Discovery

Instructor: Annette Gilchrist, PhD, Professor, Pharmacology, Midwestern University

This course will provide an understanding of the pharmacological complexities of G protein-coupled receptors (GPCRs) as well as some of the tools for studying them in an applied/drug discovery setting. The course is well-suited for discovery biologists, pharmacologists and medicinal chemists who have recently started working with GPCRs or for those who have been in the field a while and need a refresher on the latest technological advances and newest paradigms.

Afternoon | 1:30-4:30pm

SC2: Optimizing Drug Metabolism, Drug Clearance and Drug-Drug Interactions

Instructors: Zhengyin Yan, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics, Genentech Inc.

Donglu Zhang, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics, Genentech Inc.

This short course will focus on concepts that will help understand how drug clearance and drug-drug interactions (DDI) can impact decisions in drug discovery and development. Topics will include basic drug metabolism, CYP regulation, the role of bioactivation and how they all affect lead optimization. Common assays and methodologies for predicting clearance and drug-drug interactions will be discussed. Those scientists involved in medicinal chemistry, pharmacology and drug metabolism will benefit from this overview.

SC3: CNS Translational Strategies

Instructor: Changning Wang, PhD, Assistant Professor, Radiology, Massachusetts General Hospital, Harvard Medical School

A greater understanding of CNS-related disease biology and the emergence of new, improved targets and technologies has brought renewed interest in neuroscience. This short course describes the critical stages needed to translate an exciting CNS target into an effective CNS therapy by addressing challenges in biomarkers design and validation, modelling, imaging and methods to bridge the preclinical/clinical translation gap.

SC3A: Development of Micro Physiological Systems for Drug Screening

Instructors: Dean Hickman, PhD, Director, Preclinical and Site Lead for Pharmacokinetics and Drug Metabolism, Amgen

Sandra Engle, PhD, Director, Translational Cell Sciences, Stem Cells, and Genomic Engineering, Biogen

Roger D. Kamm, PhD, Green Distinguished Professor of Mechanical and Biological Engineering, Departments of Mechanical Engineering and Biological Engineering, Massachusetts Institute of Technology

Shuichi Takayama, PhD, Price Gilbert, Jr. Chair in Regenerative Engineering and Medicine, Georgia Tech

We propose a workshop for industry representatives to meet with academic researchers to align on research priorities and applications for microphysiological systems (MPS). This workshop is in response to a perceived mismatch between what companies are looking for and what academics are developing. Through participation in this workshop, the two groups will share priorities, concerns, and challenges, leaving with a shared vision that will advance the state of MPS research in a direction that is relevant for both sides. The format will include several short presentations aimed at setting the stage for fruitful discussions.

Dinner| 5:30-8:30 pm

SC4: Advanced Bioprinting Strategies for Generation of 3D Tissue Models

Instructors: Yu Shrike Zhang, PhD, Assistant Professor & Associate Bioengineer, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School

Ricky Solorzano, CEO, Allevi, Inc.

Taciana Pereira, Director, Bioengineering, Allevi, Inc.

The course will discuss a series of 3D bioprinting strategies for use in the fabrication of various physiologically or pathologically relevant human tissue models to achieve improved drug screening and personalized medicine. New advances in extrusion and stereolithographic bioprinting as well as bioink designs will be presented, along with exemplary applications in drug testing using different types of bioprinted tissue models.

SC5: Applications of Artificial Intelligence & Machine Learning in Drug Discovery & Development

Instructors: Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, The University of Michigan, Ann Arbor

Deepak K. Rajpal, Senior Scientific Director, GSK R&D

Additional Instructors to be Announced

This course aims to educate a diverse group of scientists-chemists, biologists, toxicologists, and those involved in translational and clinical research, about the growing use and applications of AI & ML. Talks start with explaining the basic terminology used and what it means, followed by discussions separating the hope from the hype. It goes into the caveats and limitations in AI and ML, while exploring ways in which it can be successfully applied in the drug discovery and development pipeline. There will be experts from various areas presenting case studies on how they have used AI/ML tools for lead optimization, target discovery, visualizing and classifying large datasets, patient stratification and more.

SC6: Targeted Protein Degradation Using PROTACs and Molecular Glues

Instructors: Eric Fischer, PhD, Assistant Professor, Cancer Biology, Dana-Farber Cancer Institute/Harvard Medical School

Davide Gianni, PhD, Associate Director, Discovery Sciences, AstraZeneca

Targeted protein degradation using molecular glues and bifunctional small molecules known as proteolysis-targeting chimeric molecules (PROTACs) are emerging as a useful tool for drug discovery, and as a new therapeutic modality for chasing previously “undruggable” targets. This course will cover the basic understanding of what these entities are, how they work and how they can be applied to target and degrade specific proteins of interest. Case studies drawn from the work that the instructors have done in their labs will also be presented.

SC7: Fit-for-Purpose Biomarker Assay Development and Validation

Instructors: John L. Allinson, FIBMS, Vice President, Biomarker Services, Immunologix Laboratories

Viswanath Devanarayan, PhD, Global Head of Statistics & Data Sciences, Charles River Laboratories

This tutorial will provide recommendations on the “fit-for-purpose” best practices in the development and validation of biomarker assays for exploratory or advanced biomarker applications. Strategies for different applications at various phases of biomarker development will be described. Key elements in the method of development and validation will be illustrated with examples, including reference to standard material, sample stability and collection integrity, validation and QC samples, validity of reference standards, calibration curve fitting methods, method optimization and feasibility studies. Special challenges in protein biomarker assays will be discussed, including strategies for moving from biomarker panels in the exploratory phase to the few markers chosen to support clinical trials, cross-validation of biomarker assays, etc.

Wednesday June 19, 2019

Dinner| 6:15-9:15 pm

SC8: Practical Phenotypic Screening


Fabien Vincent, PhD, Associate Research Fellow, Hit Discovery and Lead Profiling Group, Pfizer

Kristin Rockwell, PhD, Senior Scientist, Discovery Sciences, Pfizer

Phenotypic drug discovery is experiencing a renaissance in the pharmaceutical industry, based on its successful track record in delivering first-in-class medicines. This approach offers the promise of delivering both novel targets & chemical matter modulating a disease phenotype of interest. Although phenotypic screening may appear at first sight to be similar to target-based screening, there are some significant differences between the two approaches. These need to be properly considered and addressed to ensure the greatest likelihood of success for phenotypic screening programs. This presentation will cover a range of relevant topics with a goal of providing practical information to help prosecute such programs more effectively.

SC9: Evaluating and Characterizing in vitro Models of Drug Toxicity


Terry Van Vleet, PhD, DABT, Head of Molecular and Computational Toxicology, Department of Preclinical Safety, AbbVie

William Proctor, PhD, DABT, Associate Director/Senior Scientist, Investigative Toxicology, Department of Safety Assessment, Genentech Inc.

This short course will focus on ways to evaluate and characterize which in vitro model of drug toxicity is best suited to understand the mechanism and extent of drug toxicity involved. Topics will include a general overview of the different types of in vitro models available to assess drug toxicity, what are some of their inherent strengths and limitations, and what factors need to be considered when deciding which model to use. Those scientists involved in medicinal chemistry, DMPK, safety pharmacology and toxicology will benefit from this overview by understanding some aspects of how safety assessments are made.

SC10: In vitro and in vivo Modeling for Cancer Immunotherapy


Michael Brehm, PhD, Associate Professor, The Robert and Sandra Glass Term Chair in Diabetes, Diabetes Center of Excellence, Program in Molecular Medicine, University of Massachusetts Medical School

Barbara Joyce-Shaikh, Associate Principal Scientist, Merck Research Laboratories

Additional Instructors to be Announced

This short course will describe the use of cutting-edge models to study human tumor biology, including both in vivo and in vitro approaches to advance our understanding of interactions between human immune systems and the tumor microenvironment. The use of humanized mice to study tumor biology will be discussed, including a description of the unique models available currently, highlighting the strengths and limitations of the models and the specific application of humanized mice in the field of cancer immunotherapy. The development and use of 3D models and patient-derived organoids will also be discussed, including a description of the technologies needed to establish these models and their application to study tumor physiology, growth and specific therapies. Key concepts that will be emphasized in the course include the development of optimal strategies and study designs to effectively interrogate questions focused on immuno-oncology.

*Separate registration required.

* 活动内容有可能不事先告知作更动及调整。

Choose your language